Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA Negotiations End With Differences To Resolve In Commitment Letter

This article was originally published in The Tan Sheet

Executive Summary

The entire PDUFDA VI reauthorization process likely is more than a year from completion, but agreeing on a draft commitment letter is a major milestone for FDA and the pharma industry. It will serve as the foundation of the legislative phase expected to begin in early 2017.

You may also be interested in...



Woodcock's Legacy: CDER Organizational Improvements

In interview with the Pink Sheet, Center for Drug Evaluation and Research director discusses her 30-year career, retirement speculation, and upcoming projects.

Will PDUFA VI Fee Structure Changes Slow Revenue Growth?

User fee revenue expected to break $1bn threshold by FY 2020, but growth looks to be slower than last few years.

PDUFA Negotiations: Early Communications, Breakthrough Still On Docket

FDA and industry also talking about improvements to combination product review process as part of user fee program renewal.

Related Content

Topics

UsernamePublicRestriction

Register

PS108207

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel